QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 t2-biosystems-sells-four-t2dx-instruments-to-existing-european-distributor-amount-not-disclosed

The multiple instrument sale demonstrates commercial expansion to enable increased utilization of the T2Bacteria® Panel, the T2...

 t2-biosystems-expects-q4-2024-sepsis-product-revenue-to-be-25m-to-35m

T2 Biosystems (NASDAQ:TTOO) .

 t2-biosystems-q3-2024-gaap-eps-057-beats-064-estimate-sales-1985m-miss-2800m-estimate

T2 Biosystems (NASDAQ:TTOO) reported quarterly losses of $(0.57) per share which beat the analyst consensus estimate of $(0.64)...

 t2-biosystems-highlights-new-article-published-in-the-lancet-titled-changing-the-culture-of-blood-culture

T2 Biosystems, Inc. (NASDAQ:TTOO) (the "Company"), a leader in the rapid detection of sepsis-causing pathogens and anti...

 t2-biosystems-provides-updates-on-new-product-development-pipeline-progress

Finalizing a 510(k) premarket notification application for the T2Resistance® Panel planned to be filed with the U.S. Food and D...

 t2-biosystems--gets-australian-approval-for-its-t2candida-in-vitro-diagnostic-for-the-detection-of-sepsis-causing-fungal-pathogens-from-whole-blood

https://www.tga.gov.au/resources/artg/459987

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION